The impact of IFNL4 rs12979860 polymorphism on spontaneous clearance of hepatitis c; a case-control study

Hepatitis Monthly

Volumn 14, Issue 10, 2014, Pages

  Sharafi, Heidar ^a,b,c   Moayed Alavian, Seyed ^a,b   Behnava, Bita ^a,b   Pouryasin, Ali ^a,c,d   Keshvari, Maryam ^a,b,e  

^a Iran Hepatitis Network   (Iran)

^b Middle East Liver Diseases Center (MELD Centers)   (Iran)

^c Armin Pathobiology Laboratory   (Iran)

^d ISLAMIC AZAD UNIVERSITY   (Iran)

^e HIGH INSTITUTE FOR RESEARCH AND EDUCATION IN TRANSFUSION MEDICINE   (Iran)

Author keywords

Genetic polymorphism; Hepatitis C; Human IFNL4 protein

Indexed keywords

RESTRICTION ENDONUCLEASE;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE CLEARANCE; DNA SEQUENCE; DRUG USE; FEMALE; GENE FREQUENCY; GENOTYPE; GENOTYPING TECHNIQUE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84907831172     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.22649     Document Type: Article

References (36)

1. Thomas DL, Seef LB. Natural history of hepatitis C. Clin Liver Dis. 2005;9(3):383–98.
2. Kamal SM. Acute hepatitis C: a systematic review. Am J Gastroen-terol. 2008;103(5):1283–97.
3. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaefer M, Galai N, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284(4):450–6.
4. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798–801.
5. Shi X, Pan Y, Wang M, Wang D, Li W, Jiang T, et al. IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population. PLoS One. 2012;7(5).
6. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401.
7. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41(10):1105–9.
8. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41(10):1100–4.
9. Galmozzi E, Vigano M, Lampertico P. Systematic review with me-ta-analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection? Aliment Pharmacol Ther. 2014;39(6):569–78.
10. Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhof H, Nis-chalke HD, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology. 2010;139(5):1586–92.
11. Ruiz-Extremera A, Munoz-Gamez JA, Salmeron-Ruiz MA, de Rue-da PM, Quiles-Perez R, Gila-Medina A, et al. Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children. Hepatology. 2011;53(6):1830–8.
12. Sharaf H, Pouryasin A, Alavian SM, Behnava B, Keshvari M, Meh-rnoush L, et al. Development and Validation of a Simple, Rapid and Inexpensive PCR-RFLP Method for Genotyping of Common IL28B Polymorphisms: A Useful Pharmacogenetic Tool for Prediction of Hepatitis C Treatment Response. Hepat Mon. 2012;12(3):190–5.
13. Sharaf H, Pouryasin A, Alavian SM, Behnava B, Keshvari M, Sa-limi S, et al. Distribution of IL28B Genotypes in Iranian Patients with Chronic Hepatitis C and Healthy Individuals. Hepat Mon. 2012;12(12).
14. Kurbanov F, Abdel-Hamid M, Latanich R, Astemborski J, Mo-hamed M, Mikhail NM, et al. Genetic polymorphism in IL28B is associated with spontaneous clearance of hepatitis C virus genotype 4 infection in an Egyptian cohort. J Infect Dis. 2011;204(9):1391–4.
15. El-Awady MK, Mostafa L, Tabll AA, Abdelhafez TH, Bader El Din NG, Zayed N, et al. Association of IL28B SNP With Progression of Egyptian HCV Genotype 4 Patients to End Stage Liver Disease. Hepat Mon. 2012;12(4):271–7.
16. Montes-Cano MA, Garcia-Lozano JR, Abad-Molina C, Romero-Gomez M, Barroso N, Aguilar-Reina J, et al. Interleukin-28B genetic variants and hepatitis virus infection by diferent viral genotypes. Hepatology. 2010;52(1):33–7.
17. Beinhardt S, Aberle JH, Strasser M, Dulic-Lakovic E, Maieron A, Kreil A, et al. Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection. Gastroenterology. 2012;142(1):78–85 e2.
18. Grebely J, Petoumenos K, Hellard M, Matthews GV, Suppiah V, Applegate T, et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology. 2010;52(4):1216–24.
19. Zheng MH, Li Y, Xiao DD, Shi KQ, Fan YC, Chen LL, et al. Inter-leukin-28B rs12979860C/T and rs8099917T/G contribute to spontaneous clearance of hepatitis C virus in Caucasians. Gene. 2013;518(2):479–82.
20. Raglow Z, Thoma-Perry C, Gilroy R, Wan YJ. IL28B genotype and the expression of ISGs in normal liver. Liver Int. 2013;33(7):991–8.
21. Abe H, Hayes CN, Ochi H, Maekawa T, Tsuge M, Miki D, et al. IL28 variation afects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J Hepatol. 2011; 54(6):1094–101.
22. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology. 2010;139(2):499–509.
23. Prokunina-Olsson L, Muchmore B, Tang W, Pfeifer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013;45(2):164–71.
24. Stattermayer AF, Strassl R, Maieron A, Rutter K, Stauber R, Stras-ser M, et al. Polymorphisms of interferon-lambda4 and IL28B - efects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2014; 39(1):104–11.
25. Keshvari M, Pouryasin A, Behnava B, Sharaf H, Hajarizadeh B, Alavian SM. Letter: the rs12979860 and ss469415590 polymorphisms of IFNL4 gene are in strong linkage disequilibrium in Caucasian patients with chronic hepatitis C. Aliment Pharmacol Ther. 2014;39(3):343.
26. Hofer H, Watkins-Riedel T, Janata O, Penner E, Holzmann H, Steindl-Munda P, et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology. 2003;37(1):60–4.
27. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003;125(1):80–8.
28. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med. 1999;340(16):1228–33.
29. van den Berg CH, Grady BP, Schinkel J, van de Laar T, Molenkamp R, van Houdt R, et al. Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort. PLoS One. 2011;6(11).
30. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006;13(1):34–41.
31. Kamal SM, Kassim SK, Ahmed AI, Mahmoud S, Bahnasy KA, Hafez TA, et al. Host and viral determinants of the outcome of exposure to HCV infection genotype 4: a large longitudinal study. Am J Gas-troenterol. 2014;109(2):199–211.
32. Grebely J, Page K, Sacks-Davis R, van der Loef MS, Rice TM, Bru-neau J, et al. The efects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology. 2014;59(1):109–20.
33. Poustchi H, Esmaili S, Mohamadkhani A, Nikmahzar A, Pour-shams A, Sepanlou SG, et al. The impact of illicit drug use on spontaneous hepatitis C clearance: experience from a large cohort population study. PLoS One. 2011;6(8).
34. Grebely J, Rafa JD, Lai C, Krajden M, Conway B, Tyndall MW. Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Can J Gastroenterol. 2007;21(7):447–51.
35. Shores NJ, Maida I, Soriano V, Nunez M. Sexual transmission is associated with spontaneous HCV clearance in HIV-infected patients. J Hepatol. 2008;49(3):323–8.
36. Wiese M, Grungreif K, Guthof W, Lafrenz M, Oesen U, Porst H, et al. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany-a 25-year multicenter study. J Hepatol. 2005;43(4):590–8.